Nishida S, Tsuboi A, Tanemura A, Ito T, Nakajima H, Shirakata T, Morimoto S, Fujiki F, Hosen N, Oji Y, Kumanogoh A, Kawase I, Oka Y, Azuma I, Morita S, Sugiyama H
Morimoto S, Fujiki F, Kondo K, Nakajima H, Kobayashi Y, Inatome M, Aoyama N, Nishida Y, Tsuboi A, Oka Y, Nishida S, Nakata J, Hosen N, Oji Y, Sugiyama H.
Kanai T, Ito Z, Oji Y, Suka M, Nishida S, Takakura K, Kajihara M, Saruta M, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Shimodaira S, Okamoto M, Sugiyama H, Koido S
Oncology letters 16(2) 2682-2692 Aug 2018 [Refereed]
Nakata J, Nakae Y, Kawakami M, Morimoto S, Motooka D, Hosen N, Fujiki F, Nakajima H, Hasegawa K, Nishida S, Tsuboi A, Oji Y, Oka Y, Kumanogoh A, Sugiyama H
British journal of haematology 182(2) 287-290 Jul 2018 [Refereed]
Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, Nishida S, Nakata J, Nakae Y, Takashima S, Shirakata T, Nakajima H, Hasegawa K, Kida H, Kijima T, Morimoto S, Fujiki F, Tsuboi A, Morii E, Morita S, Sakamoto J, Kumanogoh A, Oka Y, Okumura M, Sugiyama H
International journal of cancer 142(11) 2375-2382 Jun 2018 [Refereed]
Nishida S, Ishikawa T, Egawa S, Koido S, Yanagimoto H, Ishii J, Kanno Y, Kokura S, Yasuda H, Oba MS, Sato M, Morimoto S, Fujiki F, Eguchi H, Nagano H, Kumanogoh A, Unno M, Kon M, Shimada H, Ito K, Homma S, Oka Y, Morita S, Sugiyama H
Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, Watanabe K, Yoshida M, Satoh K, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Manabe M, Ichihara H, Aoyama Y, Mugitani A, Nakao T, Hino M, Uchibori R, Ozawa K, Baba Y, Terakura S, Wada N, Morii E, Nishimura J, Takeda K, Oji Y, Sugiyama H, Takagi J, Kumanogoh A
Nature medicine 23(12) 1436-1443 Dec 2017 [Refereed]
Phase I study of CpG ODN(K3), a novel toll-like receptor 9 agonist, for advanced lung cancer: Interim analyses of safety and immunity in subcutaneous injection cohort
12th Meeting of the Japanese Vaccine Adjuvant Research Consortium 22 Jan 2019
Randomized phases II study of WT1 peptide vaccine in combination with gemcitabine for advanced pancreaticcancer: association between clinical efficacy and immune response in metastatic pancreatic cancer patinets.
9th International Conference on WT1 in Human Neoplasia 29 Jun 2018
Randomized phases II study of WT1 peptide vaccine plus gemcitabine for advanced pancreatic ductal adenocarcinoma (PDAC): Clinical efficacy and immune response.
Sumiyuki Nishida, Takeshi Ishikawa, Satoshi Kokura, Shinichi Egawa, Shigeo Koido, Hiroaki Yasuda, Hiroaki Yanagimoto, Jun Ishii, Yoshihide Kanno, Mari S. Ohba, Maho Sato, Soyoko Morimoto, Hidetoshi Eguchi, Hiroaki Nagano, Sadamu Homma, Yoshihiro Oka, Satoshi Morita, and Haruo Sugiyama.
ASCO Annual Meeting 2016 3 Jun 2016
進行性膵癌に対するgemcitabine療法と併用したWT1ペプチドを用いる癌ワクチン療法(WT1 peptide-based cancer vaccine in combination with gemcitabine for advanced pancreatic cancer)
